Hepatitis C in the rituximab era

James M. Foran

doi:10.1182/blood-2010-09-307827

Hepatitis C in the rituximab era

James M. Foran

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Abstract

In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

Original language	English (US)
Pages (from-to)	5081-5082
Number of pages	2
Journal	Blood
Volume	116
Issue number	24
DOIs	https://doi.org/10.1182/blood-2010-09-307827
State	Published - Dec 9 2010

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2010-09-307827

Cite this

@article{178842daa4664ece85107a95c8be6b27,

title = "Hepatitis C in the rituximab era",

abstract = "In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.",

author = "Foran, {James M.}",

year = "2010",

month = dec,

day = "9",

doi = "10.1182/blood-2010-09-307827",

language = "English (US)",

volume = "116",

pages = "5081--5082",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "24",

}

TY - JOUR

T1 - Hepatitis C in the rituximab era

AU - Foran, James M.

PY - 2010/12/9

Y1 - 2010/12/9

N2 - In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

AB - In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

UR - http://www.scopus.com/inward/record.url?scp=78650071123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650071123&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-09-307827

DO - 10.1182/blood-2010-09-307827

M3 - Comment/debate

C2 - 21148335

AN - SCOPUS:78650071123

SN - 0006-4971

VL - 116

SP - 5081

EP - 5082

JO - Blood

JF - Blood

IS - 24

ER -

Hepatitis C in the rituximab era

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this